Vasostatin基因抑制裸鼠种植性肝癌血管生成的实验研究  

Vasostatin gene therapy suppresses the angiogenesis of implant hepatocellular carcinoma in nude mice

作　　者：邹方[1] 修鹏[1] 徐宗珍[1] 李杰[1] 

机构地区：[1]山东大学附属千佛山医院肝胆外科,山东济南250014

出　　处：《中国现代普通外科进展》2010年第2期89-92,共4页Chinese Journal of Current Advances in General Surgery

基　　金：山东省科技攻关课题(2007GG20002021)

摘　　要：目的:探讨人血管内皮抑制素Vasostatin基因对裸鼠种植性肝癌生长及肿瘤新生血管生成和细胞凋亡的影响。方法:建立裸鼠肝癌种植瘤模型,采用Vasostatin基因质粒(VAS组)及空壳质粒(对照组)进行瘤体内电转染,观察治疗后肿瘤生长情况,计算肿瘤体积及抑瘤率,应用免疫组织化学技术检测肿瘤微血管密度变化,TUNEL法检测肿瘤细胞凋亡情况。结果:VAS组抑瘤率为31.73%。对照组、VAS组肿瘤质量分别为(1.23±0.82)g和(0.81±0.62)g;微血管密度分别为18.26±1.72和5.62±0.59;肿瘤细胞凋亡指数分别为6.25±1.32和16.48±0.96,2组间差异均有统计学意义(P<0.05)。结论:人血管内皮抑制素Vasostatin基因对裸鼠种植性肝癌生长具有明显的抑制作用,可促进肿瘤细胞的凋亡,进而影响肿瘤生长。Objective： To investigate the effect of Vasostatin gene therapy in nude mice model of hepatocellular carcinoma. Methods： The Vasostatin expression plasmids were electrobloted into hepatocellular tumours of nude mice induced by dimethylbenzanthracine. The tumor inhibiting rate was calculated, the tumor microvessel density（MVD）was measured by the immunohistochemical staining and tumor apoptosis were examined with TUNEL. Results： The tumor weight of the control group and VAS group was（1.23±0.82）g and（0.81±0.62）g respectively, the MVD was 18.26±1.72 and 5.62±0.59, the AI was 6.25±1.32 and 16.48±0.96 , and there were significant differences among them（P〈0.05）. Conclusions： The Vasostatin gene therapy should be considered as an approach to suppress the growth of hepatocellular carcinoma.

关 键 词：VASOSTATIN 肝肿瘤 血管生成 细胞凋亡 基因治疗 小鼠 裸 

分 类 号：R735.7[医药卫生—肿瘤]